About Skyepharma
Skyepharma is a Healthcare company based in London (United Kingdom) founded in 1996. Developer of small molecule based oral and inhalation products for the treatment of various diseases. The company has since been acquired. Its focus areas include Diversified Pharmaceuticals.
Company details
SkyePharma is developing small molecule-based oral and inhalation products for the treatment of various diseases. It uses its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. Its Geomatrix and Geoclock technologies enable controlled and timed-release versions of orally administered therapeutics Soctec, a novel gastric retention technology was specifically developed for molecules requiring absorption in the stomach or upper part of the intestine. Its inhalation technologies include formulation as well as device technologies and encompass Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs)
- Headquarters London, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website skyepharma.com
- Social LinkedIn
- Acquired by Vectura (Mar 2016)
- Latest Funding Round$38.7M (USD), Debt – Conventional
May 2015
- InvestorsBarclays
& 1 more
Funding Insights of Skyepharma
- Total Rounds 3
- Last Round Debt – Conventional — $38.7M
- First Round $68.53M
(Dec 2006)
- Investors Count 1
All 3 funding rounds of Skyepharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2015 | $38.7M | Debt – Conventional | – | – | |
| Mar 2014 | $219.31M | Post-IPO | – | – | – |
| Dec 2006 | $68.53M | Debt – Conventional | – | – | – |
2 investors in total: 2 institutional.
Investors in Skyepharma
Skyepharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Barclays and Phillips Medisize.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified financial services are provided across global markets. | 1690 | home.barclays | London, United Kingdom | |
Inhaled therapeutics for respiratory diseases are developed. | 1997 | vectura.com | Chippenham, United Kingdom |
Investor details for Skyepharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Skyepharma
4 dated milestones of Skyepharma across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Skyepharma is founded.
- Funding First funding round of $68.5M.
- Funding Latest funding round, Debt – Conventional, of $38.7M.
- Exit Acquired by Vectura.
Web traffic of Skyepharma
Websites that share an audience with Skyepharma (skyepharma.com).
Websites whose visitors overlap most with Skyepharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| crescendobiologics.com | 100% | #13,705,548 | View details | ||
| emisphere.com | 99% | View details | |||
| kamada.com | 96% | 10.4K | #2,182,321 | View details | |
| intellipharmaceutics.com | 95% | View details | |||
| pharmaxis.com.au | 95% | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Skyepharma
Complete news archive for Skyepharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Skyepharma
Skyepharma was founded in 1996 and raised its 1st funding round 10 years after it was founded.
Skyepharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
SkyePharma is developing small molecule-based oral and inhalation products for the treatment of various diseases. It uses its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. Its Geomatrix and Geoclock technologies enable controlled and timed-release versions of orally administered therapeutics Soctec, a novel gastric retention technology was specifically developed for molecules requiring absorption in the stomach or upper part of the intestine. Its inhalation technologies include formulation as well as device technologies and encompass Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs).
Skyepharma has 2 investors. Key investors include Barclays, and Phillips Medisize.
Yes. Skyepharma was acquired by Vectura in March 2016.